Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

OBJECTIVES: This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA). METHODS: Treatment-emergent adverse events (TEAEs) and laboratory data from five randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B, van Vollenhoven, Ronald F, Winthrop, Kevin L, Zerbini, Cristiano A F, Tanaka, Yoshiya, Bessette, Louis, Zhang, Ying, Khan, Nasser, Hendrickson, Barbara, Enejosa, Jeffrey V, Burmester, Gerd R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892382/
https://www.ncbi.nlm.nih.gov/pubmed/33115760
http://dx.doi.org/10.1136/annrheumdis-2020-218510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892382/
https://www.ncbi.nlm.nih.gov/pubmed/33115760
http://dx.doi.org/10.1136/annrheumdis-2020-218510

Ejemplares similares